A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming
Article
Article
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with limited therapeutic options in the relapsed or refractory setting. Selinexor, a selective inhibitor of nuclear export targeting X...
LCC LCC:MedicineIdioma English
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access